Jump to: Page Content, Section Navigation, Site Navigation, Site Search, Account Information, or Site Tools.
|
|
Technical CommentsResponse to Comment on "Obestatin, a Peptide Encoded by the Ghrelin Gene, Opposes Ghrelin's Effects on Food Intake"
We cannot reproduce our original findings on obestatin binding and activation of GPR39 receptors in vitro. However, we can reproduce our original findings on the in vivo effects of obestatin in mice (decreases in food intake, gastric emptying responses, and body weight gain) under precise experimental conditions. Further studies are needed to reveal the exact relation between obestatin and the G proteincoupled receptor GPR39.
1 Division of Reproductive Biology, Department of Obstetrics and Gynecology, Stanford University School of Medicine, Stanford, CA 94305, USA.
2 Johnson and Johnson Pharmaceutical Research and Development, a Division of Janssen Pharmaceutica NV, Beerse, Belgium. * To whom correspondence should be addressed. E-mail: aaron.hsueh{at}stanford.edu Based on a bioinformatic prediction of a hormone flanking the mature ghrelin peptide, we purified obestatin from the rat stomach and custom-synthesized the peptide to demonstrate its biological activities in vivo andinvitro (1). Following the publication of these findings, our collaborators indicated that the initial batch of obestatin (GL Biochem. Ltd., Shanghai, China) contained impurities. We subsequently used purified obestatin from other sources (Penta Biotech, Freemont, California, and Global Peptide, Ft. Collins, Colorado) (2) and could not repeat the binding of iodinated obestatin to tissue homogenates or recombinant GPR39 receptors. In addition, purified obestatin does not stimulate cAMP (cyclic adenosine monophosphate) and SRE (serum-responsive element) responses by cells expressing recombinant GPR39. These findings are consistent with the findings of Chartrel et al. (3) and two recent reports (4, 5). Because up to four iodine molecules can be incorporated into the obestatin peptide during iodination (6), we hypothesize that purified obestatin lost bioactivity after iodination, whereas our initial contaminated peptide retained some bioactivity. We note that the phenotypes of GPR39 mutant mice are at least partially consistent with the role of GPR39 as the obestatin receptor (7). We repeated our original in vivo findings (decreases in food intake, gastric emptying responses, and body weight gain) using purified obestatin from different sources (Penta Biotech or Global Peptide). As shown in Fig. 1, an exact time course (15 min) of food replacement delay after obestatin administration is essential to demonstrate the suppressive effect of this hormone with a short circulating half-life (8, 9). The apparent short half-life of obestatin could contribute to the observed suppression of food intake by some laboratories (911) but not others (1215). Since publication of our report (1), obestatin has been shown to suppress drinking responses (16), improve memory (11), decrease growth hormone secretion in vivo (9), regulate sleep (17), activate cortical neurons (18), and stimulate proliferation of retinal pigment epithelial cells (19). Further studies are needed to reveal the exact role of obestatin as a metabolic and brain/gut hormone.
Received for publication 20 November 2006. Accepted for publication 11 January 2007.
The editors suggest the following Related Resources on Science sites:In Science Magazine
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
|
Science. ISSN 0036-8075 (print), 1095-9203 (online)